COVID-19 vaccines for patients with cancer: benefits likely outweigh risks.
COVID-19 vaccines for patients with cancer: benefits likely outweigh risks.
复制标题
DOI：
10.1186/s13045-021-01046-w
复制
发表时间：
2021-02-27
影响因子：
28.5
通讯作者：
Li Z
中科院分区：
文献类型：
--
作者：
Hwang JK;Zhang T;Wang AZ;Li Z
自COVID-19大流行开始不到一年，已有10种针对SARS-CoV-2的疫苗被批准至少有限度地使用，另有60多种疫苗正在临床试验中。随着全球COVID-19病例数继续快速增加，这一迅速成就令人兴奋，并在非常需要的时候到来。目前有两种疫苗被批准全面使用，都建立在mRNA和脂质纳米技术平台上，这是mRNA技术20年来的一个成功故事。对于癌症患者，在恶性肿瘤和/或治疗引起免疫改变的情况下，围绕这些疫苗的安全性和有效性出现了问题。我们总结了目前领先的COVID-19候选疫苗和接受免疫调节性癌症治疗的患者接种疫苗的数据。目前大多数癌症治疗方法不应阻止保护性免疫的产生。我们呼吁在这一领域进行更多的研究，并建议大多数癌症患者在可能的情况下接种COVID疫苗。
Less than a year since the start of the COVID-19 pandemic, ten vaccines against SARS-CoV-2 have been approved for at least limited use, with over sixty others in clinical trials. This swift achievement has generated excitement and arrives at a time of great need, as the number of COVID-19 cases worldwide continues to rapidly increase. Two vaccines are currently approved for full use, both built on mRNA and lipid nanotechnology platforms, a success story of mRNA technology 20 years in the making. For patients with cancer, questions arise around the safety and efficacy of these vaccines in the setting of immune alterations engendered by their malignancy and/or therapies. We summarize the current data on leading COVID-19 vaccine candidates and vaccination of patients undergoing immunomodulatory cancer treatments. Most current cancer therapeutics should not prevent the generation of protective immunity. We call for more research in this area and recommend that the majority of patients with cancer receive COVID vaccinations when possible.
登录
查看更多内容
影响因子：
51.1
作者：
Garassino, Marina Chiara;Whisenant, Jennifer G.;Horn, Leora
通讯作者：
Horn, Leora
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group
影响因子：
28.5
作者：
García-Suárez J;de la Cruz J;Cedillo Á;Llamas P;Duarte R;Jiménez-Yuste V;Hernández-Rivas JÁ;Gil-Manso R;Kwon M;Sánchez-Godoy P;Martínez-Barranco P;Colás-Lahuerta B;Herrera P;Benito-Parra L;Alegre A;Velasco A;Matilla A;Aláez-Usón MC;Martos-Martínez R;Martínez-Chamorro C;Susana-Quiroz K;Del Campo JF;de la Fuente A;Herráez R;Pascual A;Gómez E;Pérez-Oteyza J;Ruiz E;Alonso A;González-Medina J;Martín-Buitrago LN;Canales M;González-Gascón I;Vicente-Ayuso MC;Valenciano S;Roa MG;Monteliu PE;López-Jiménez J;Escobar CE;Ortiz-Martín J;Diez-Martin JL;Martinez-Lopez J;Asociación Madrileña de Hematología y Hemoterapia (AMHH)
通讯作者：
Asociación Madrileña de Hematología y Hemoterapia (AMHH)
影响因子：
8
作者：
Cho, Alice;Bradley, Bridget;Wrammert, Jens
通讯作者：
Wrammert, Jens
影响因子：
5.4
作者：
Bolles, Meagan;Deming, Damon;Baric, Ralph S.
通讯作者：
Baric, Ralph S.